fax: +41 31 941 03 76
Article first published online: 8 MAY 2013
Copyright © 2013 American Association for the Study of Liver Diseases
Volume 58, Issue 1, pages 229–238, July 2013
How to Cite
Beyoğlu, D., Imbeaud, S., Maurhofer, O., Bioulac-Sage, P., Zucman-Rossi, J., Dufour, J.-F. and Idle, J. R. (2013), Tissue metabolomics of hepatocellular carcinoma: Tumor energy metabolism and the role of transcriptomic classification. Hepatology, 58: 229–238. doi: 10.1002/hep.26350
Potential conflict of interest: Nothing to report.
Supported in part by National Institutes of Health/National Institute of Allergy and Infectious Diseases grant U19 AI067773-07/08 (to J.R.I.); Bernerische und Schweizerische Krebsliga, Sasella Foundation, and the Hassan Badawi Foundation Against Liver Cancer (to J.R.I., J.F.D.); this work was also the PAIR-CHC project NoFLIC (funded by INCa and Association pour la recherche contre le Cancer, ARC), the Réseau national CRB Foie and BioIntelligence (OSEO).
- Issue published online: 24 JUN 2013
- Article first published online: 8 MAY 2013
- Accepted manuscript online: 5 MAR 2013 01:34PM EST
- Manuscript Accepted: 19 FEB 2013
- Manuscript Received: 4 DEC 2012
Hepatocellular carcinoma (HCC) is one of the commonest causes of death from cancer. A plethora of metabolomic investigations of HCC have yielded molecules in biofluids that are both up- and down-regulated but no real consensus has emerged regarding exploitable biomarkers for early detection of HCC. We report here a different approach, a combined transcriptomics and metabolomics study of energy metabolism in HCC. A panel of 31 pairs of HCC tumors and corresponding nontumor liver tissues from the same patients was investigated by gas chromatography-mass spectrometry (GCMS)-based metabolomics. HCC was characterized by ∼2-fold depletion of glucose, glycerol 3- and 2-phosphate, malate, alanine, myo-inositol, and linoleic acid. Data are consistent with a metabolic remodeling involving a 4-fold increase in glycolysis over mitochondrial oxidative phosphorylation. A second panel of 59 HCC that had been typed by transcriptomics and classified in G1 to G6 subgroups was also subjected to GCMS tissue metabolomics. No differences in glucose, lactate, alanine, glycerol 3-phosphate, malate, myo-inositol, or stearic acid tissue concentrations were found, suggesting that the Wnt/β-catenin pathway activated by CTNNB1 mutation in subgroups G5 and G6 did not exhibit specific metabolic remodeling. However, subgroup G1 had markedly reduced tissue concentrations of 1-stearoylglycerol, 1-palmitoylglycerol, and palmitic acid, suggesting that the high serum α-fetoprotein phenotype of G1, associated with the known overexpression of lipid catabolic enzymes, could be detected through metabolomics as increased lipid catabolism. Conclusion: Tissue metabolomics yielded precise biochemical information regarding HCC tumor metabolic remodeling from mitochondrial oxidation to aerobic glycolysis and the impact of molecular subtypes on this process. (HEPATOLOGY 2013)